These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10332054)

  • 1. Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR.
    Comets E; Mentré F; Nimmerfall F; Kawai R; Mueller I; Marbach P; Vonderscher J
    J Control Release; 1999 May; 59(2):197-205. PubMed ID: 10332054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits.
    Comets E; Mentré F; Kawai R; Nimmerfall F; Marbach P; Vonderscher J
    J Pharm Sci; 2000 Sep; 89(9):1123-33. PubMed ID: 10944377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide.
    Petersen H; Bizec JC; Schuetz H; Delporte ML
    BMC Res Notes; 2011 Sep; 4():344. PubMed ID: 21906300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
    Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships.
    Grass P; Marbach P; Bruns C; Lancranjan I
    Metabolism; 1996 Aug; 45(8 Suppl 1):27-30. PubMed ID: 8769375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal injection of octreotide acetate.
    Robertson JE; Westra I; Woltering EA; Winthrop KL; Barrie R; O'Dorisio TM; Holmes D
    J Ocul Pharmacol Ther; 1997 Apr; 13(2):171-7. PubMed ID: 9090617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
    Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
    Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly].
    Priou A; Levesque G; Simonetta C; Lancranjan I; Roger P; Jaquet P
    Ann Endocrinol (Paris); 1995; 56(3):213-8. PubMed ID: 7677407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects.
    Zhou H; Chen TL; Marino M; Lau H; Miller T; Kalafsky G; McLeod JF
    Br J Clin Pharmacol; 2000 Dec; 50(6):543-52. PubMed ID: 11136293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
    Garland J; Buscombe JR; Bouvier C; Bouloux P; Chapman MH; Chow AC; Reynolds N; Caplin ME
    Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC; Noble S; Goa KL
    Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects.
    Chen T; Miller TF; Prasad P; Lee J; Krauss J; Miscik K; Kalafsky G; McLeod JF
    J Clin Pharmacol; 2000 May; 40(5):475-81. PubMed ID: 10806600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.